





Casamento, Charles J. - The Wall Street Transcript













































 





































Charles J. Casamento
CHARLES J. CASAMENTO is Chairman, President and Chief Executive Officer
of Questcor Pharmaceuticals, Inc. He joined RiboGene, Inc., in June
1993. On November 17, 1999, RiboGene and Cypros merged to form Questcor
Pharmaceuticals, Inc. The company currently has five products on the
market in the US. In the fourth quarter of 2003, driven by the
introduction of a new product, Nascobal, Questcor revenues hit a record
level and the company recorded its first profitable quarter with net
income of $324,000. Mr. Casamento closed 37 partnership, product
acquisition, R&D collaborations and merger transactions with Questcor.
Previously, Mr. Casamento was President and Chief Executive Officer of
Interneuron Pharmaceuticals, Inc., which he co-founded in February 1989.
From 1986 to 1989, he was Senior Vice President at Genzyme Corporation.
From 1983 to 1986, he was Vice President, Business Development and
Planning at the Critical Care Division of American Hospital Supply
Corporation, and from 1970 to 1983 he held managerial positions with
Johnson & Johnson, Hoffmann-LaRoche and Sandoz. Mr. Casamento received
an MBA in 1971 from Iona College, New Rochelle, New York and a BS in
Pharmacy in 1968 from Fordham University College of Pharmacy in New York
City. He is a member of the Board of Directors of Cortex
Pharmaceuticals, Inc., in Irvine, California; SuperGen Inc. in Dublin,
California; and the Catholic Medical Mission Board, a non-profit
organization, in New York, New York which serves the medical needs of
people in Third World countries. He is a licensed pharmacist in the
states of New York and New Jersey.
Related Interviews:Charles Casamento - Questcor Pharmaceuticals Inc (qsc)May 03, 2004Charles Casamento - Questcor Pharmaceuticals Inc (qsc)October 17, 2003Charles Casamento - Questcor Pharmaceuticals Inc (qsc)March 24, 2003Charles Casamento - Questcor Pharmaceuticals Inc (qsc)March 11, 2003Charles Casamento - Questcor Pharmaceuticals Inc (qsc)August 26, 2002Charles Casamento - Questcor Pharmaceuticals Inc (qsc)June 02, 2002Charles Casamento - Questcor Pharmaceuticals Inc (qsc)August 06, 2001Charles J. Casamento -  Questcor Pharmaceuticals Inc (qsc)January 24, 2000Charles J. Casamento -  Ribogene Inc (rbo)February 08, 1999







CartLatest NewsJames Abate of Centre Asset Management Sees Consumer Demand Driving New Stock HighsMalcolm E. Polley of Stewart Capital and How to Play the Health Care StocksTimothy Biltz, CEO of Lumos Networks Identifies the Key Component for Future 5G NetworksThe Wall Street Transcript is a completely unique resource for investors and business researchers.Over 20,000 CEO, Equity Analyst and Money Manager InterviewsSubscribe now!Sign Up For Newsletter Weekly email with New In-Depth Interviews


Email: 



Most Popular InterviewsDelivering Long-Term Results with a Risk-Managed Growth FundJames A. Abate Published July 20, 2017 in Investing StrategiesCompanies covered: AMAT JNJ COH RL COG NVDA ADBE ATVI KLAC AMZN NFLX GOOG FB GLW MU 005930 000660 WFM JWN CMG GPS EQT RICE SPLS Buy ($25)Finding Investments with Favorable Risk and Reward OpportunitiesHenry  Beukema Published July 19, 2017 in Investing StrategiesCompanies covered: ORCL MSFT NSRGY AMZN WFM LRLCY AGN LNR Buy ($25)Better Returns and Lower Risk in the Midcap SpaceMalcolm E. Polley Published July 18, 2017 in Investing StrategiesCompanies covered: PRAA HURN FII FL NKE AMZN WFM WBA RAD Buy ($25)Most Popular ReportsWireless Communications & Telecom Published July 14, 2017Buy ($175)Investing Strategies Published July 11, 2017Buy ($175)Investing Strategies Published June 30, 2017Buy ($175) 






Top Company Interviews






Register for a Free Account to gain greater access to
            The Wall Street Transcript right now




CEO INTERVIEWSInterview with the President and CEO: Lumos Networks Corp. (NASDAQ:LMOS)Interview with the Corporate VP of Business Development, Strategy and Investor Relations: DSP Group, Inc. (NASDAQ:DSPG)Interview with the CEO and Director: Tactile Systems Technology, Inc. (NASDAQ:TCMD) 

SECTOR ROUNDTABLESNatural Gas Weighs Heavy On E&P Near-Term ProspectsRoundtable Forum:optimism Despite Uncertainty In For-profit EducationRoundtable Forum:a Shift In Focus To Natural Gas From Oil 

MONEY MANAGER INTERVIEWSDelivering Long-Term Results with a Risk-Managed Growth FundFinding Investments with Favorable Risk and Reward OpportunitiesBetter Returns and Lower Risk in the Midcap Space 

ANALYST INTERVIEWSAnalyzing the Secular Drivers Within Communications Infrastructure and TelecomSatellite Companies Benefiting from Growth in Data TrafficIncreased Focus on Content as Consumers Shift to Digital Consumption 




Subscribe Today!







                Since 1963
                © The Wall Street Transcript 1997-2016
Terms and Conditions
Privacy Policy  
            





https://www.twst.com/wp-admin/admin-ajax.php

Pin It on Pinterest





































Share This





Twitter





Facebook





Google+





Gmail





LinkedIn








































×





Join now for free!
Already a member?






First Name 





Last Name 





Email address *








Create new account
 


or create an account with a social network.

Join with Facebook


Join with Twitter


Join with Google








Username or Email address: *





Password: *






LoginJoin now! | Forgot password?
 


or login using a social network


Log in with Facebook


Log in with Twitter


Log in with Google














Charles J. Casamento MBA : Executive Profile & Biography - Bloomberg









































  





















































































July 24, 2017 9:12 AM ET
Biotechnology

Company Overview of International Stem Cell Corporation



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Charles J. Casamento MBA Executive Director, International Stem Cell CorporationAgeTotal Calculated CompensationThis person is connected to 6 Board Members in 6 different organizations across 10 different industries.See Board Relationships72$67,395
Background

		Mr. Charles J. Casamento, also known as Chuck, MBA, has been Principal of The Sage Group, Inc. since May 2007. Mr. Casamento has over 38 years of extensive experience in marketing, business development and Executive management in pharmaceutical, biotechnology and medical products companies. Mr. Casamento served as the President and Chief Executive Officer of Osteologix Holdings plc (alternate name: Osteologix Inc.), from October 18, 2004 to April 3, 2007, Chief Accounting ... Officer until April 3, 2007 and Consultant from April 3, 2007 to July 3, 2007. He was Founder of Questcor Pharmaceuticals. He served as the Chairman, Chief Executive Officer and President of Questcor Pharmaceuticals Inc. from November 1999 to August 6, 2004 and Consultant since August 6, 2004. Prior to joining Questcor Pharmaceuticals Inc., he served as the Chairman, Chief Executive Officer and President of RiboGene, Inc. from June 1993 to November 1999. Mr. Casamento co-founded Interneuron Pharmaceuticals, Inc., and served as its President and Chief Executive Officer from March 1989 to May 1993. From July 1985 to March 1989, he served as the Senior Vice President and General Manager, Pharmaceuticals & Biochemicals at Genzyme Corporation. From December 1970 to March 1989, He has held management positions at Novartis, Johnson & Johnson, Hoffmann LaRoche Inc., Sandoz Inc. and American Hospital Supply Corp., where he served as the Vice President, Business Development and Strategic Planning for the Critical Care Division from January 1983 to July 1985. He has been the Chairman of Relmada Therapeutics, Inc. since June 15, 2017 and as its Independent Director since July 14, 2015. He served as the Chairman of RespireRx Pharmaceuticals Inc.(also known as Cortex Pharmaceuticals Inc.) from August 10, 2012 to March 22, 2013. He served as Vice Chairman of The Catholic Medical Mission Board. He has been an Executive Director of The Sage Group, Inc. since May 2007. He has been a Director of AzurRx BioPharma, Inc. since March 5, 2017. He has been an Independent Director of Astex Pharmaceuticals, Inc. (alternate name: SuperGen Inc.) since September 2002 and an Executive Director at International Stem Cell Corporation since June 21, 2010. He has been a Director of KineMed, Inc. since November 2013. He serves as a Director on the boards of eight public biotechnology/pharmaceutical companies. He serves as a Director of the Catholic Medical Mission Board in New York City, a not-for-profit organization. He served as a Director of Lifepoint Inc. from June 16, 2000 to October 2003. He served as an Independent Director of VIVUS Inc. from April 17, 2008 to July 2013. He served as an Independent Director of Cortex Pharmaceuticals Inc. from July 1997 to August 10, 2012. He served as a Director Questcor Pharmaceuticals Inc. Mr. Casamento served as a Director of Osteologix until June 07, 2007. He served as a Director of RiboGene, Inc. He is also a Licensed Pharmacist in the States of New York and New Jersey. Mr. Casamento holds a bachelor's degree in Pharmacy from Fordham University and an M.B.A. degree from Iona College.Read Full Background




Corporate Headquarters
5950 Priestly DriveCarlsbad, California 92008United StatesPhone: 760-940-6383Fax: 760-476-0600
Board Members Memberships
2002-PresentIndependent DirectorAstex Pharmaceuticals, Inc.2007-PresentExecutive DirectorThe Sage Group, Inc.2010-PresentExecutive DirectorInternational Stem Cell Corporation2013-PresentDirectorKineMed, Inc.2015-PresentChairmanRelmada Therapeutics, Inc.2017-PresentDirectorAzurRx BioPharma, Inc.
Education
BS Fordham UniversityMBA Iona College
Other Affiliations
Endo Pharmaceuticals Solutions Inc.RiboGene, Inc.Astex Pharmaceuticals, Inc.VIVUS, Inc.RespireRx Pharmaceuticals Inc.Questcor Pharmaceuticals, Inc.LifePoint, Inc.Fordham UniversityIona CollegeThe Sage Group, Inc.Relmada Therapeutics, Inc.KineMed, Inc.Osteologix Holdings plcAzurRx BioPharma, Inc.


Annual Compensation
				There is no Annual Compensation data available.
				Stocks Options
				There is no Stock Options data available.
				Total Compensation
Total Annual Cash Compensation$32,500Total Calculated Compensation$67,395




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONNamePosition/CompanyCompensationOlav  Hellebø MBA, BBAChief Executive Officer and DirectorReNeuron Group plc$405.0KMarc H. Hedrick M.D.Chief Executive Officer, President & DirectorCytori Therapeutics, Inc.$450.0KDavid E. Jorden CPAChief Executive Officer, Chief Financial Officer and Executive DirectorNuo Therapeutics, Inc.$260.4KMichael  Tomas Chief Executive Officer, President, Chief Financial Officer and DirectorU.S. Stem Cell, Inc.$1.2MRichard J. Daly Chairman of the Board, CEO, President and Interim Principal Financial & Accounting OfficerNeuralstem, Inc.$551.7KCompensation as of Fiscal Year 2016.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact International Stem Cell Corporation, please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close















































 



 Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors 
         










    










 













 











 



















Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors
        																																																		
              

          Globally recognized leader in drug development and commercialization assumes Board leadership as Relmada advances clinical development of drug candidates to treat CNS disorders
        
















 News provided by
Relmada Therapeutics, Inc.  
Jun 15, 2017, 08:30 ET









 Share this article




























































NEW YORK, June 15, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Charles J. Casamento has been appointed chairman of the company's board of directors.  Mr. Casamento has been a member of the Relmada Therapeutics board of directors since July 2015 and is also chairman of the audit committee and a member of the compensation and the corporate governance committees.








Since 2007, Mr. Casamento has been executive director and principal of The Sage Group, a health care advisory group.  Previously he was president and CEO of Osteologix and founder, chairman and CEO of Questcor Pharmaceuticals. In 2015 Questcor was acquired by Mallinckrodt for approximately $6 billion.  He also served as president, CEO and chairman of RiboGene Inc. and was co-founder, president and CEO of Indevus (formerly Interneuron Pharmaceuticals). In 2006 Indevus was acquired by Endo Pharmaceuticals for approximately $650 million.  He has also held senior management positions at Genzyme Corporation, American Hospital Supply, Johnson & Johnson, Hoffmann-LaRoche and Sandoz. He has served as a director of eleven other pharmaceutical/biotechnology companies and has been on the board of two not for profit organizations. 
"Charles Casamento has been an outstanding member of the Relmada board of directors, and in his new role as chairman his insights and expertise will play an even more important role in guiding and advancing our business strategy in the years ahead," said Sergio Traversa, chief executive officer of Relmada.
About Relmada Therapeutics, Inc. 
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. For more information, please visit Relmada's website at: www.relmada.com.  
Forward-Looking Statements 
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.
Contact
Media Contact:  Bill Berry  Berry & Company Public Relations  Tel: 212-253-8881  bberry@berrypr.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/charles-j-casamento-appointed-chairman-of-relmada-therapeutics-board-of-directors-300474590.html
SOURCE Relmada Therapeutics, Inc.
 Related Links

http://www.relmada.com



 

















Jun 21, 2017, 08:00 ET
Preview: Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics




















May 18, 2017, 08:00 ET
Preview: Relmada Therapeutics Announces Settlement of Legal Action with Laidlaw & Company








My News


  Release contains wide tables.	  View fullscreen.






 Also from this source




 











Jun 28, 2017, 08:00 ET
                                  				                                                                                     
                              Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the...








 











Jun 21, 2017, 08:00 ET
                                  				                                                                                     
                              Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at...





 Explore
 More news releases in similar topics

  Biotechnology
  Health Care & Hospitals
  Medical Pharmaceuticals
Personnel Announcements








 You just read:
Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors


 News provided by
Relmada Therapeutics, Inc.  
Jun 15, 2017, 08:30 ET








 Share this article









































 











Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In

















Search











Searching for your content...









Advanced Search












































 











Charles J. Casamento - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Charles J. Casamento
Board Member at International Stem Cell Corporation


View Full Profile
Are you Charles J. Casamento? Claim your profile


 


Sign up for Equilar Atlas and view Charles J. Casamento's full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Charles J. Casamento's  network and community.
												FOLLOW changes in Charles J. Casamento's employment and money-in-motion.
												CONNECT with Charles J. Casamento through your network of contacts.
												








Charles J. Casamento's Executive Work History


Current


Board Member, 
International Stem Cell Corporation


Board Member, 
AzurRx BioPharma, Inc.


Past
To view Charles J. Casamento's complete executive work history, sign up now
Age
71

 
 


Charles J. Casamento's Biography



Charles J. Casamento has been a director since June 2010. Mr. Casamento is currently Executive Director and Principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies, since 2007. He was the president and CEO of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. From 1999 through 2004, he served as chairman of the board, president and CEO of Questcor Pharmaceuticals, Inc. which was subsequently acquired by Mallinckrodt. Mr. Casamento formerly served as RiboG ...
(Read More)

			Charles J. Casamento has been a director since June 2010. Mr. Casamento is currently Executive Director and Principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies, since 2007. He was the president and CEO of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. From 1999 through 2004, he served as chairman of the board, president and CEO of Questcor Pharmaceuticals, Inc. which was subsequently acquired by Mallinckrodt. Mr. Casamento formerly served as RiboGene, Inc.'s president, CEO and chairman of the board from 1993 through 1999 until it merged with Cypros to form Questcor. He was co-founder, president and CEO of Interneuron Pharmaceuticals, Inc. (Indevus), a biopharmaceutical company, from 1989 until 1993. Indevus was eventually acquired by Endo. Mr. Casamento has also held senior management positions at Genzyme Corporation, where he was senior vice president, pharmaceuticals and biochemicals; American Hospital Supply, where he was vice president of business development and strategic planning for the Critical Care Division; Johnson & Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc. Mr. Casamento also serves on the Board of Directors of Relmada Therapeutics and AzurRx BioPharma. He is Chairman of the Audit Committee at Relmada. During his career he has sat on the boards of twelve public companies and has also been a Director and Vice Chairman of The Catholic Medical Missions Board, a large not for profit organization providing health care services to third world countries. He has served as a guest lecturer at Fordham University and is on the Science Council of Fordham University. He holds a bachelor's degree in Pharmacy from Fordham University and an M.B.A. from Iona College and was originally licensed to practice pharmacy in the states of New York and New Jersey. We believe that Mr. Casamento's qualifications to serve on our Board include his significant experience as chief executive officer in various life sciences companies and his service on several other boards, which bring valuable knowledge and insights to the Board.
		
Source: International Stem Cell Corporation on 04/28/2017
		
	

 






Sign up for Equilar Atlas and view Charles J. Casamento's full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Charles J. Casamento. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Charles J. Casamento's  network and community.
												FOLLOW changes in Charles J. Casamento's employment and money-in-motion.
												CONNECT with Charles J. Casamento through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Charles J. Casamento


















Charles J. Casamento's Connections (88)





Sign up now to view Charles J. Casamento's 88 connections »









Denis R. Burger
Chief Science Officer and Vice Chairman of the Board, CytoDyn Inc.









Roger G. Stoll
Chairman of the Board, Delcath Systems, Inc.









Jeffrey D. Janus
Former Consultant, International Stem Cell Corporation









Martin Buckland
Former Chief Business Officer, Astex Pharmaceuticals









Allan R. Goldberg
Former Board Member, Astex Pharmaceuticals









Brian Lundstrom
Former Employee, International Stem Cell Corporation









Ismail Kola
Board Member, Athersys, Inc.









Mario M. Rosati
Board Member, Sanmina Corporation









John F. Benedik
Former Board Member, RespireRx









Timothy Haines
Former Board Member, Sientra, Inc.








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Elon R. Musk
CEO and Chairman, Tesla









Daniel A. DeMatteo
Executive Chairman, GameStop Corp.









David J. O'Connor
President and CEO, The Madison Square Garden Company












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

� 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993






















Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors - GuruFocus.com 


















Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors - GuruFocus.com










Home




 Homepage


 Membership Levels


 Membership Data Coverage


 Complete Stock List


 Founder's Message


 The Book


 FREE Trial






Screeners


Value Screens 


 All-In-One Screener


 Industry Overview


 Ben Graham Net-Net


 Undervalued Predictable


 Buffett-Munger Screener


 Magic Formula (Greenblatt)


 Historical Low P/S List


 Historical Low P/B List


 Peter Lynch Screen


 High Short Interest


 52-Week/3Y/5Y Lows


 52-Week/3Y/5Y Highs


 Predictable Companies


 S&P 500 Grid


 Dividend Stocks


 Spin Off List




Downloads | Tools


  Excel Add-In GURUF


 Manual of Stocks™


 Download Financial Data


 Download Guru Portfolios


 Download Stock PDFs


 Download Insider Data


  API


 Mobile App




Strategies


 Performances


 Buffett-Munger


 Undervalued Predictable


 Low P/S


 Low P/B


 Broadest Owned


 Most Weighted






Gurus




 Latest Guru Picks


 Real Time Picks


 List of Gurus (Personalize)


 Gurus Portfolios


 Scoreboard


 Top 10 Holdings View


 Sector Picks


 International Picks


 Aggregated Portfolio


 Consensus Picks


 Guru Bargains


 Hot Picks


 Industry Trends


 Geographic Trend


 ETFs


 Options


 European Shorting






Insiders




 All Insiders


 CEO Buys/Sales


 CFO Buys/Sales


 Insider Cluster


 Guru+Insider Double Buys


 Triple Buys/Sales


 Insider Trends


 Canadian Insider


 Dutch Insider






Market


Market Valuation


 Economic Data


 Industry Overview


 Market-Cap/GDP Valuation


 Global Market Valuation


 Shiller P/E


 Shiller P/E By Sectors


 Buffett Assets Allocation




By Country


 USA


 Australia


 Canada


 China


 Germany


 India


 Japan


 UK


 More...






Articles


Articles


 Editor's Picks


 GuruFocus Research


 Value Ideas


 Interviews with Gurus


 Top Ranked


 Value Idea Contest


 Videos


 Following Authors




Submit Articles


 Writers Wanted


 Value Contest Winners


 Submit Articles Online


 My Articles






Conference




 Value Conference


 Speakers


 Location/Venue


 Register


 After Conference Gathering (Free Drinks)






Tutorials




 Tutorials & Webinars


 FAQ


 Contact Us






Log In




 Free Sign-up


 Log In


 7-Day Free Trial 






Subscribe




 Free Trial ($399/Year)


 Refer a Friend & Earn $50














Search
Compare

Search ▾










Get 7-Day Free Trial



My Portfolios▾
                        
Portfolios Overview
Create New Portfolio
Portfolio Contest


My Gurus▾
                        
Quick Browse
Personalize

My Gurus

Premium Gurus 
Premium Plus Investors 


























 How  to  use  GuruFocus  -  Tutorials
 What  Is  in  the  GuruFocus  Premium  Membership?
A DIY Guide on How to Invest Using Guru Strategies

 PRNewswireArticles 
Bookmark

Print


Tweet















Bookmark Name:









			This page was added to your Bookmark.
		



Members Only. Please Sign Up or Log In first.




			Bookmark of this page has been deleted.
		



Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of DirectorsJune 15, 2017 |  About: 
OTCPK:RLMD  +0%
OTCPK:RLMD  +0%
OTCPK:RLMD  +0%




Globally recognized leader in drug development and commercialization assumes Board leadership as Relmada advances clinical development of drug candidates to treat CNS disorders
PR Newswire
NEW YORK, June 15, 2017

NEW YORK, June 15, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Charles J. Casamento has been appointed chairman of the company's board of directors.  Mr. Casamento has been a member of the Relmada Therapeutics board of directors since July 2015 and is also chairman of the audit committee and a member of the compensation and the corporate governance committees.

Warning! GuruFocus has detected 3 Warning Signs with OTCPK:RLMD. Click here to check it out. 
OTCPK:RLMD 30-Year Financial DataThe intrinsic value of OTCPK:RLMDPeter Lynch Chart of OTCPK:RLMD

Since 2007, Mr. Casamento has been executive director and principal of The Sage Group, a health care advisory group.  Previously he was president and CEO of Osteologix and founder, chairman and CEO of Questcor Pharmaceuticals. In 2015 Questcor was acquired by Mallinckrodt for approximately $6 billion.  He also served as president, CEO and chairman of RiboGene Inc. and was co-founder, president and CEO of Indevus (formerly Interneuron Pharmaceuticals). In 2006 Indevus was acquired by Endo Pharmaceuticals for approximately $650 million.  He has also held senior management positions at Genzyme Corporation, American Hospital Supply, Johnson & Johnson, Hoffmann-LaRoche and Sandoz. He has served as a director of eleven other pharmaceutical/biotechnology companies and has been on the board of two not for profit organizations. 
"Charles Casamento has been an outstanding member of the Relmada board of directors, and in his new role as chairman his insights and expertise will play an even more important role in guiding and advancing our business strategy in the years ahead," said Sergio Traversa, chief executive officer of Relmada.
About Relmada Therapeutics, Inc. 
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. For more information, please visit Relmada's website at: www.relmada.com.  
Forward-Looking Statements 
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.
Contact
Media Contact:  Bill Berry  Berry & Company Public Relations  Tel: 212-253-8881  [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/charles-j-casamento-appointed-chairman-of-relmada-therapeutics-board-of-directors-300474590.html
SOURCE  Relmada Therapeutics, Inc.









  Currently 0.00/512345  Rating:  0.0/5 (0 votes)  


Subscribe
            via Email
Subscribe RSS





Comments


Please leave your comment:






More GuruFocus Links



Latest Guru Picks
Value Strategies


Warren Buffett Portfolio
Ben Graham Net-Net


Real Time Picks
Buffett-Munger Screener


Aggregated Portfolio
Undervalued Predictable


ETFs, Options
Low P/S Companies


Insider Trends
10-Year Financials


52-Week Lows
Interactive Charts


Model Portfolios
DCF Calculator


RSS Feed 
Monthly Newsletters


The  All-In-One Screener
Portfolio Tracking Tool










                        GuruFocus has detected 3 Warning Signs with Relmada Therapeutics Inc $OTCPK:RLMD.                    

                        More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
                    





















→Performances of the stocks mentioned by  PRNewswire




→User
            Generated Screeners

PortfolioPlus10 yr ProfitabilityTaekgyun Kovalue2PortfolioPlusStrong B/S ScreenConnorMCommodityConnorMLosingExUSConnorMLosingHOLKLSUMini Group IT Healthcare MaterLuddyshooting starsPeterZmiiHKfilmwatcherStable Dividend Growers

→OTCPK:RLMD Price Chart





$0.75 (1y: -65%)



→Guru NewsShould You Believe in Target's Turnaround? by Harsh Jain6 Investment Ideas From Industry Insiders  by Bram de HaasWhy Investors Should Consider PepsiCo by Mayank MarwahHere's Why You Should Pay Attention to Carter's by Omar Venerio→Value Ideas6 Investment Ideas From Industry Insiders  by Bram de HaasWhy Investors Should Consider PepsiCo by Mayank MarwahHere's Why You Should Pay Attention to Carter's by Omar VenerioVoya Financial, a Risky Financial Bet?  by Mark Yu→Guru InterviewsPodcast Episode 3: Healthcare Investing Pro Mindy Perry by Holly LaFonPodcast Episode 4: Interview With Legendary Investor Jean-Marie Eveillard by Holly LaFon23 Questions With the Founder of WayUndervalued.com by PJ PahygiannisGuruFocus Interview: Orbimed Guru Sam Isaly on Investing in New Era of Healthcare by Holly LaFon→Top Ranked ArticlesSome Thoughts on Holding Cash by The Science of HittingMohnish Pabrai Crushing It With 2 Best-Performing Car Companies, Ferrari and Fiat by Holly LaFonBerkshire and Blue Chip Stamps by The Science of HittingWhat Can We Learn From the Energy Market?  by Grahamites
→You May Also LikeRelmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive DisorderDell Technologies Championship Boston-Area Charity Partners NamedInfraREIT Announces Agreements for Simultaneous Rate Case Dismissal and the Exchange of Retail Distribution Assets for Transmission Assets from OncorDebra DeShong Joins MGM Resorts International As Vice President Of Global Industry AffairsDelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM



 













Select portfolio(s):








                        Create a new portfolio



Why you are interested?



            Your selection and notes will be stored in your portfolio.
        


Login to add portfolio















Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
                    | Earn affiliate commissions by embedding GuruFocus Charts

                                                GuruFocus Affiliate Program: Earn up to $400 per referral.  ( Learn More) 













Home  About   Jobs    Advertise    Site Map    Term of Use    Privacy Policy     RSS    Mobile App     Email Alerts    Referral Program    Affiliate Program    FAQ    Contact Us
                               

                © 2004-2017                GuruFocus.com, LLC. All Rights Reserved.
            


                    Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC.



                    Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.


















GF Chat {{numOfNotice}}




























×
Manage BookMarks





Close








FEEDBACK






















Charles J. Casamento - Ribogene Inc (rbo) - The Wall Street Transcript
















































 






































Healthcare >> CEO Interviews >> February 8, 1999 Charles J. Casamento –  Ribogene Inc (rbo)
CHARLES J. CASAMENTO is Chairman, President and Chief Executive Officer
of Questcor Pharmaceuticals, Inc. He joined RiboGene, Inc., in June
1993. On November 17, 1999, RiboGene and Cypros merged to form Questcor
Pharmaceuticals, Inc. The company currently has five products on the
market in the US. In the fourth quarter of 2003, driven by the
introduction of a new product, Nascobal, Questcor revenues hit a record
level and the company recorded its first profitable quarter with net
income of $324,000. Mr. Casamento closed 37 partnership, product
acquisition, R&D collaborations and merger transactions with Questcor.
Previously, Mr. Casamento was President and Chief Executive Officer of
Interneuron Pharmaceuticals, Inc., which he co-founded in February 1989.
From 1986 to 1989, he was Senior Vice President at Genzyme Corporation.
From 1983 to 1986, he was Vice President, Business Development and
Planning at the Critical Care Division of American Hospital Supply
Corporation, and from 1970 to 1983 he held managerial positions with
Johnson & Johnson, Hoffmann-LaRoche and Sandoz. Mr. Casamento received
an MBA in 1971 from Iona College, New Rochelle, New York and a BS in
Pharmacy in 1968 from Fordham University College of Pharmacy in New York
City. He is a member of the Board of Directors of Cortex
Pharmaceuticals, Inc., in Irvine, California; SuperGen Inc. in Dublin,
California; and the Catholic Medical Mission Board, a non-profit
organization, in New York, New York which serves the medical needs of
people in Third World countries. He is a licensed pharmacist in the
states of New York and New Jersey. Profile


TWST: First, give us a background summary on the company, enoughinformation to put us into context as what you see as your business andwhat you see as your company today. Mr. Casamento:
    

Join for free to read a longer excerpt or purchase this article

Already a member? Login here 









CartLatest NewsJames Abate of Centre Asset Management Sees Consumer Demand Driving New Stock HighsMalcolm E. Polley of Stewart Capital and How to Play the Health Care StocksTimothy Biltz, CEO of Lumos Networks Identifies the Key Component for Future 5G NetworksThe Wall Street Transcript is a completely unique resource for investors and business researchers.Over 20,000 CEO, Equity Analyst and Money Manager InterviewsSubscribe now!Sign Up For Newsletter Weekly email with New In-Depth Interviews


Email: 



Most Popular InterviewsDelivering Long-Term Results with a Risk-Managed Growth FundJames A. Abate Published July 20, 2017 in Investing StrategiesCompanies covered: AMAT JNJ COH RL COG NVDA ADBE ATVI KLAC AMZN NFLX GOOG FB GLW MU 005930 000660 WFM JWN CMG GPS EQT RICE SPLS Buy ($25)Finding Investments with Favorable Risk and Reward OpportunitiesHenry  Beukema Published July 19, 2017 in Investing StrategiesCompanies covered: ORCL MSFT NSRGY AMZN WFM LRLCY AGN LNR Buy ($25)Better Returns and Lower Risk in the Midcap SpaceMalcolm E. Polley Published July 18, 2017 in Investing StrategiesCompanies covered: PRAA HURN FII FL NKE AMZN WFM WBA RAD Buy ($25)Most Popular ReportsWireless Communications & Telecom Published July 14, 2017Buy ($175)Investing Strategies Published July 11, 2017Buy ($175)Investing Strategies Published June 30, 2017Buy ($175) 






Top Company Interviews






Register for a Free Account to gain greater access to
            The Wall Street Transcript right now




CEO INTERVIEWSInterview with the President and CEO: Lumos Networks Corp. (NASDAQ:LMOS)Interview with the Corporate VP of Business Development, Strategy and Investor Relations: DSP Group, Inc. (NASDAQ:DSPG)Interview with the CEO and Director: Tactile Systems Technology, Inc. (NASDAQ:TCMD) 

SECTOR ROUNDTABLESNatural Gas Weighs Heavy On E&P Near-Term ProspectsRoundtable Forum:optimism Despite Uncertainty In For-profit EducationRoundtable Forum:a Shift In Focus To Natural Gas From Oil 

MONEY MANAGER INTERVIEWSDelivering Long-Term Results with a Risk-Managed Growth FundFinding Investments with Favorable Risk and Reward OpportunitiesBetter Returns and Lower Risk in the Midcap Space 

ANALYST INTERVIEWSAnalyzing the Secular Drivers Within Communications Infrastructure and TelecomSatellite Companies Benefiting from Growth in Data TrafficIncreased Focus on Content as Consumers Shift to Digital Consumption 




Subscribe Today!







                Since 1963
                © The Wall Street Transcript 1997-2016
Terms and Conditions
Privacy Policy  
            





https://www.twst.com/wp-admin/admin-ajax.php

Pin It on Pinterest





































Share This





Twitter





Facebook





Google+





Gmail





LinkedIn








































×





Join now for free!
Already a member?






First Name 





Last Name 





Email address *








Create new account
 


or create an account with a social network.

Join with Facebook


Join with Twitter


Join with Google








Username or Email address: *





Password: *






LoginJoin now! | Forgot password?
 


or login using a social network


Log in with Facebook


Log in with Twitter


Log in with Google














	Charles J Casamento Appointed Chairman Of Relmada Therapeutics Board Of Directors













































Employer:
Login
Post Jobs


Job Seeker:
Login
Sign Up

























Search Life Sciences Jobs





Search Job Title Only












Radius:
Miles



Km80.5
















                 News | News By Subject | News by Disease |  
    News By Date | Search News



















Get Our FREEIndustry eNewsletter

email:


*
            
*
            



















 

 






Charles J. Casamento Appointed Chairman Of Relmada Therapeutics Board Of Directors  











Tweet








6/15/2017 8:55:52 AM




  Life Sciences Jobs
 


  &bullet; Newest Jobs - Last 24 Hours


  &bullet; California Jobs


  &bullet; Massachusetts Jobs


  &bullet; New Jersey Jobs


  &bullet; Maryland Jobs


  &bullet; Washington Jobs


  View More Jobs


NEW YORK, June 15, 2017/PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Charles J. Casamento has been appointed chairman of the company's board of directors.  Mr. Casamento has been a member of the Relmada Therapeutics board of directors since July 2015 and is also chairman of the audit committee and a member of the compensation and the corporate governance committees.Since 2007, Mr. Casamento has been executive director and principal of The Sage Group, a health care advisory group.  Previously he was president and CEO of Osteologix and founder, chairman and CEO of Questcor Pharmaceuticals. In 2015 Questcor was acquired by Mallinckrodt for approximately $6 billion.  He also served as president, CEO and chairman of RiboGene Inc. and was co-founder, president and CEO of Indevus (formerly Interneuron Pharmaceuticals). In 2006 Indevus was acquired by Endo Pharmaceuticals for approximately $650 million.  He has also held senior management positions at Genzyme Corporation, American Hospital Supply, Johnson & Johnson, Hoffmann-LaRoche and Sandoz. He has served as a director of eleven other pharmaceutical/biotechnology companies and has been on the board of two not for profit organizations. "Charles Casamento has been an outstanding member of the Relmada board of directors, and in his new role as chairman his insights and expertise will play an even more important role in guiding and advancing our business strategy in the years ahead," said Sergio Traversa, chief executive officer of Relmada.About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. For more information, please visit Relmada's website at: www.relmada.com.  Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.ContactMedia Contact:  Bill Berry  Berry & Company Public Relations  Tel: 212-253-8881  bberry@berrypr.comTo view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/charles-j-casamento-appointed-chairman-of-relmada-therapeutics-board-of-directors-300474590.htmlSOURCE  Relmada Therapeutics, Inc.






                Read at
                BioSpace.com







Related News
Relmada Therapeutics Announces Settlement Of Legal Action With Laidlaw & Company Aziyo Biologics Banks Some Cash And Former Osiris (OSIR) Exec As Its New CEO  Relmada Therapeutics Announces FDA Fast Track Designation For D-Methadone For Adjunctive Treatment Of Major Depressive Disorder  Effective Immediately: Bristol-Myers Squibb (BMY) Exec to Take the Reins at Kleo Relmada Therapeutics Release: Announces FDA Acceptance Of IND And Authorization To Commence Phase 2a Clinical Trial For D-Methadone  What Would 6 Industry Icons Do Differently If Given The Chance To Be CEO Again  Relmada Therapeutics Release: Pharma To Provide An Update On The Development Plan For LevoCap ER  Alexion (ALXN) Poaches Biogen (BIIB)'s Longtime CFO  Relmada Therapeutics Announces Issuance Of Key U.S. Patent Covering D-Methadone, An NMDA Receptor Antagonist, For The Treatment Of Depression And Other Psychiatric Symptoms  Struggling Teva (TEVA) Wants To Overhaul Board By Nominating 4 New Directors  




Please enable JavaScript to view the comments powered by Disqus.
comments powered by Disqus






















                            •
                            BioSpace.com










                            •
                            Relmada Therapeutics




             
        





                            •
                            Biotech/Pharma - Personnel




             
        















                              
                            

                              
                             
                              
                            

                              
                            








                 





























 






Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors :: Relmada Therapeutics, Inc. (RLMD)
































 















Press Releases
Investors 




Home
Investors
News / Events
Press Releases
Charles J. Casamento Appointed Chairman of...












	Investors
 


Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors


 Download as PDF

June 15, 2017

Globally recognized leader in drug development and commercialization assumes Board leadership as Relmada advances clinical development of drug candidates to treat CNS disorders

NEW YORK, June 15, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Charles J. Casamento has been appointed chairman of the company's board of directors.  Mr. Casamento has been a member of the Relmada Therapeutics board of directors since July 2015 and is also chairman of the audit committee and a member of the compensation and the corporate governance committees.



Since 2007, Mr. Casamento has been executive director and principal of The Sage Group, a health care advisory group.  Previously he was president and CEO of Osteologix and founder, chairman and CEO of Questcor Pharmaceuticals. In 2015 Questcor was acquired by Mallinckrodt for approximately $6 billion.  He also served as president, CEO and chairman of RiboGene Inc. and was co-founder, president and CEO of Indevus (formerly Interneuron Pharmaceuticals). In 2006 Indevus was acquired by Endo Pharmaceuticals for approximately $650 million.  He has also held senior management positions at Genzyme Corporation, American Hospital Supply, Johnson & Johnson, Hoffmann-LaRoche and Sandoz. He has served as a director of eleven other pharmaceutical/biotechnology companies and has been on the board of two not for profit organizations. 
"Charles Casamento has been an outstanding member of the Relmada board of directors, and in his new role as chairman his insights and expertise will play an even more important role in guiding and advancing our business strategy in the years ahead," said Sergio Traversa, chief executive officer of Relmada.
About Relmada Therapeutics, Inc. 
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. For more information, please visit Relmada's website at: www.relmada.com.  
Forward-Looking Statements 
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.
Contact
Media Contact:  Bill Berry  Berry & Company Public Relations  Tel: 212-253-8881  bberry@berrypr.com


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/charles-j-casamento-appointed-chairman-of-relmada-therapeutics-board-of-directors-300474590.html
SOURCE  Relmada Therapeutics, Inc.

Released June 15, 2017







 

Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of DirectorsHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreTry Yahoo Finance on Firefox »YahooSearchSearchSign inU.S. Markets open in 17 mins.S&P Futures2,468.25-1.25 (-0.05%)Dow Futuresundefined (0)Nasdaq Futures5,917.75-1.00 (-0.02%)Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of DirectorsPR NewswireJune 15, 2017ReblogShareTweetShareGlobally recognized leader in drug development and commercialization assumes Board leadership as Relmada advances clinical development of drug candidates to treat CNS disordersNEW YORK, June 15, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Charles J. Casamento has been appointed chairman of the company's board of directors.  Mr. Casamento has been a member of the Relmada Therapeutics board of directors since July 2015 and is also chairman of the audit committee and a member of the compensation and the corporate governance committees.Relmada Therapeutics Corporate LogoMoreSince 2007, Mr. Casamento has been executive director and principal of The Sage Group, a health care advisory group.  Previously he was president and CEO of Osteologix and founder, chairman and CEO of Questcor Pharmaceuticals. In 2015 Questcor was acquired by Mallinckrodt for approximately $6 billion.  He also served as president, CEO and chairman of RiboGene Inc. and was co-founder, president and CEO of Indevus (formerly Interneuron Pharmaceuticals). In 2006 Indevus was acquired by Endo Pharmaceuticals for approximately $650 million.  He has also held senior management positions at Genzyme Corporation, American Hospital Supply, Johnson & Johnson, Hoffmann-LaRoche and Sandoz. He has served as a director of eleven other pharmaceutical/biotechnology companies and has been on the board of two not for profit organizations."Charles Casamento has been an outstanding member of the Relmada board of directors, and in his new role as chairman his insights and expertise will play an even more important role in guiding and advancing our business strategy in the years ahead," said Sergio Traversa, chief executive officer of Relmada.About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. For more information, please visit Relmada's website at: www.relmada.com.  Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.Read MoreContactMedia Contact:  Bill Berry  Berry & Company Public Relations  Tel: 212-253-8881  bberry@berrypr.comTo view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/charles-j-casamento-appointed-chairman-of-relmada-therapeutics-board-of-directors-300474590.htmlReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextGrab builds out war chest in a fight for car-share dominanceAssociated PressA 'big fall' in markets is coming as traders put record cash to workBusiness InsiderHere’s the next ‘FANG’ stock that’s set to explodeCNBC64 years after Korean War, North still digging up bombsAssociated PressAetna CEO Bertolini: How tech plays into the future of healthcareYahoo Finance VideoAetna's CEO Mark Bertolini on the future of the health care systemYahoo FinanceHow 2 life-threatening events changed how Aetna's CEO views health careYahoo FinanceBlue Apron just got a flood of bullish ratings from Wall Street, and its shares are flyingBusiness InsiderWhy sparkling water sales could spike by 20% in 2017Yahoo FinanceAetna CEO Bertolini: Why he pays his employees to sleepYahoo Finance VideoWhy it might be ‘dangerous’ for IBM to turn itself around: professorYahoo FinanceAmazon Is Going Underwater. Seriously.FortuneJeb Bush calls out Republicans who criticized Obama over Russia, but have been silent on the Trump-Russia probeBusiness InsiderKKR to buy WebMD in $2.8 billion dealReutersAetna CEO Bertolini: How his own accident and son’s cancer changed his journeyYahoo Finance VideoCall of the week: Now's the time to 'buy' ChipotleYahoo Finance64 years after Korean War, North still digging up bombsJames: Well you should not have tried to push Communism  onto the south now should you?Join the Conversation1 / 5192








